| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
,
* Integrated Biomedical Sciences Graduate Program, Department of Molecular Virology, Immunology and Medical Genetics, and Department of Surgery, Arthur G. James Comprehensive Cancer Center and Solove Research Institute, Ohio State University, Columbus, OH 43210
Bacterial DNA contains a high frequency of unmethylated CpG motifs that stimulate immune cells via TLR9. NK cells express a low-affinity activating receptor for the Fc portion of IgG (Fc
RIIIa), but were not thought to express TLR9 protein. The direct response of NK cells to CpG oligodeoxynucleotides (ODN) in the presence of FcR stimulation was investigated. Human NK cells cultured in the presence of CpG ODN plus immobilized IgG or Ab-coated tumor cells secreted large amounts of IFN- (>2000 pg/ml), whereas cells stimulated with Ab alone, CpG ODN alone, or Ab and control ODN produced negligible amounts. Enhanced secretion of IL-8, macrophage-derived chemokine, and MIP-1
was also observed after costimulation. NK cell cytokine production was not the result of interactions with APCs or their cytokine products. Flow cytometric analysis revealed that 36 ± 3.5% of human NK cells expressed basal levels of TLR9. TLR9 expression in human NK cells was confirmed by immunoblot analysis. Only TLR9-expressing NK cells responded to CpG ODN and Ab, because cytokine production was not observed in NK cells from TLR9-deficient mice. Mice receiving CpG ODN and HER2/neu-positive tumor cells treated with an anti-HER2 Ab exhibited enhanced systemic levels of IFN- compared with mice receiving either agent alone. TLR9–/– animals reconstituted with TLR9+/+ NK cells secreted IFN- in response to CpG ODN and Ab-coated tumor cells. These findings indicate that CpG ODN can directly enhance the NK cell cytokine response to Ab-coated targets via activation of TLR9.
This article has been cited by other articles:
|
|
 |
|
  K. Takeda, S. W. Dow, N. Miyahara, T. Kodama, T. Koya, C. Taube, A. Joetham, J.-W. Park, A. Dakhama, R. M. Kedl, et al. Vaccine-Induced CD8+ T Cell-Dependent Suppression of Airway Hyperresponsiveness and Inflammation J. Immunol., July 1, 2009; 183(1): 181 - 190. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. N. Toka, C. K. Nfon, H. Dawson, and W. T. Golde Accessory-Cell-Mediated Activation of Porcine NK Cells by Toll-Like Receptor 7 (TLR7) and TLR8 Agonists Clin. Vaccine Immunol., June 1, 2009; 16(6): 866 - 878. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. D. LoBue, J. M. Thompson, L. Lindesmith, R. E. Johnston, and R. S. Baric Alphavirus-Adjuvanted Norovirus-Like Particle Vaccines: Heterologous, Humoral, and Mucosal Immune Responses Protect against Murine Norovirus Challenge J. Virol., April 1, 2009; 83(7): 3212 - 3227. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Aurisicchio, D. Peruzzi, A. Conforti, S. Dharmapuri, A. Biondo, S. Giampaoli, A. Fridman, A. Bagchi, C. T. Winkelmann, R. Gibson, et al. Treatment of Mammary Carcinomas in HER-2 Transgenic Mice through Combination of Genetic Vaccine and an Agonist of Toll-Like Receptor 9 Clin. Cancer Res., March 1, 2009; 15(5): 1575 - 1584. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. A. Taylor, M. J. Ehrhardt, C. J. Lees, A. Panoskaltsis-Mortari, A. M. Krieg, A. H. Sharpe, W. J. Murphy, J. S. Serody, H. Hemmi, S. Akira, et al. TLR agonists regulate alloresponses and uncover a critical role for donor APCs in allogeneic bone marrow rejection Blood, October 15, 2008; 112(8): 3508 - 3516. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Roda, R. Parihar, A. Lehman, A. Mani, S. Tridandapani, and W. E. Carson III Interleukin-21 Enhances NK Cell Activation in Response to Antibody-Coated Targets J. Immunol., July 1, 2006; 177(1): 120 - 129. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. S. Gorski, E. L. Waller, J. Bjornton-Severson, J. A. Hanten, C. L. Riter, W. C. Kieper, K. B. Gorden, J. S. Miller, J. P. Vasilakos, M. A. Tomai, et al. Distinct indirect pathways govern human NK-cell activation by TLR-7 and TLR-8 agonists Int. Immunol., July 1, 2006; 18(7): 1115 - 1126. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. F. Eisenbeis, G. B. Lesinski, M. Anghelina, R. Parihar, D. Valentino, J. Liu, P. Nadella, P. Sundaram, D. C. Young, M. Sznol, et al. Phase I Study of the Sequential Combination of Interleukin-12 and Interferon Alfa-2b in Advanced Cancer: Evidence for Modulation of Interferon Signaling Pathways by Interleukin-12 J. Clin. Oncol., December 1, 2005; 23(34): 8835 - 8844. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
